Pernix Sleep Inc  

(Public, NASDAQ:SOMX)   Watch this stock  
Find more results for SOMX
Mar 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.29 - 5.44
Open     -
Vol / Avg. 0.00/55,721.00
Mkt cap 21.57M
P/E     -
Div/yield     -
EPS -3.08
Shares     -
Beta 2.62
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -209.42% -366.95%
Operating margin -210.07% -355.26%
EBITD margin - -350.88%
Return on average assets -151.48% -146.39%
Return on average equity -564.13% -194.98%
Employees 36 -
CDP Score - -


Suite 200, 440 Stevens Avenue
United States - Map
+1-858-8766500 (Phone)
+1-858-5091761 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pernix Sleep Inc, formerly Somaxon Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of branded products and late-stage product candidates. The Company operates in one segment, which is the development and commercialization of pharmaceutical products. The Company�s focus is on commercial activities relating to Silenor. As of December 31, 2011, the clinical development program for Silenor included four Phase III clinical trials. In June 2011, it entered into agreements with Paladin Labs Inc. (Paladin), under which Paladin had the right to commercialize Silenor in Canada, South America, the Caribbean and Africa, subject to the receipt of marketing approval in each such territory. In March 2013, Pernix Therapeutics Holdings Inc acquired the Company.